{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:54:27Z","timestamp":1768456467825,"version":"3.49.0"},"reference-count":30,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 10520 grant"],"award-info":[{"award-number":["MFAG 10520 grant"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Collecting duct carcinoma (CDC) is rare and aggressive histology of kidney cancers. Although different therapeutic approaches have been tested, the 2-year survival remains very poor. Since CDC exhibits overlapping features with urothelial carcinoma, the analysis of shared molecular alterations could provide new insights into the understanding of this rare disease and also therapeutic options. We collected 26 CDC cases, and we assessed HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in-situ hybridization (FISH) according to 2018 ASCO\/CAP HER2-testing recommendations. Six out of twenty-six (23%) tumors showed HER2 positive staining. In particular, 3+ score was present in 2\/6 cases (33%), 2+ in 3\/6 cases (50%) and 1+ in 1\/6 cases (17%). The 6 HER2+ tumors were also analyzed by FISH to assess gene copy number. One out of six CDC with IHC 3+ was also HER2 amplified, showing an average HER2 copy number \u22654.0 (10.85) and a HER2\/CEP17 ratio \u2265 (5.63), while the 5\/6 cases were HER2 negative. Based on the 2018 ASCO\/CAP guidelines overall, 2\/26 CDC cases (8%) were HER2+. The present study provides evidence for testing, in future studies, HER2 to assess its clinical value as a novel target for the treatment of this highly malignant cancer.<\/jats:p>","DOI":"10.3390\/cancers12113345","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T20:17:52Z","timestamp":1605212272000},"page":"3345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-0987","authenticated-orcid":false,"given":"Manuela","family":"Costantini","sequence":"first","affiliation":[{"name":"Department of Urology, IRCCS Regina Elena National Cancer Institute\u2014Rome, via Elio Chianesi 53, 00144 Rome, Italy"}]},{"given":"Carla Azzurra","family":"Amoreo","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Regina Elena National Cancer Institute\u2014Rome, via Elio Chianesi 53, 00144 Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-0523","authenticated-orcid":false,"given":"Liborio","family":"Torregrossa","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, 56126 Pisa, Italy"}]},{"given":"Greta","family":"Al\u00ec","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, 56126 Pisa, Italy"}]},{"given":"Enrico","family":"Munari","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sacro Cuore Don Calabria, 37024 Negrar, Italy"},{"name":"Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jeronimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) &amp; Porto Comprehensive Cancer Center (P.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) &amp; Porto Comprehensive Cancer Center (P.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"given":"Sara","family":"Petronilho","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) &amp; Porto Comprehensive Cancer Center (P.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9225-1795","authenticated-orcid":false,"given":"Umberto","family":"Capitanio","sequence":"additional","affiliation":[{"name":"Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}]},{"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[{"name":"Unit of Pathology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-3010","authenticated-orcid":false,"given":"Nazareno","family":"Suardi","sequence":"additional","affiliation":[{"name":"Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}]},{"given":"Maria Teresa","family":"Landi","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA"}]},{"given":"Umberto","family":"Anceschi","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS Regina Elena National Cancer Institute\u2014Rome, via Elio Chianesi 53, 00144 Rome, Italy"}]},{"given":"Aldo","family":"Brassetti","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS Regina Elena National Cancer Institute\u2014Rome, via Elio Chianesi 53, 00144 Rome, Italy"}]},{"given":"Vito Michele","family":"Fazio","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, 00128 Rome, Italy"},{"name":"CNR-Institute of Translational Pharmacology, 00133 Roma, Italy"}]},{"given":"Michele","family":"Gallucci","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rome, La Sapienza, Rome, Viale del Policlinico 155, 00161 Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-9025","authenticated-orcid":false,"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[{"name":"Department of Urology, IRCCS Regina Elena National Cancer Institute\u2014Rome, via Elio Chianesi 53, 00144 Rome, Italy"}]},{"given":"Steno","family":"Sentinelli","sequence":"additional","affiliation":[{"name":"Department of Pathology, IRCCS Regina Elena National Cancer Institute\u2014Rome, via Elio Chianesi 53, 00144 Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6364-727X","authenticated-orcid":false,"given":"Maria Luana","family":"Poeta","sequence":"additional","affiliation":[{"name":"Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, via Orabona 4, 70126 Bari, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(06)00502-7","article-title":"Collecting duct (Bellini duct) renal cell carcinoma: A nationwide survey in Japan","volume":"176","author":"Noriaki","year":"2006","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1752-1947-2-304","article-title":"Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: A case series","volume":"2","author":"Nakamura","year":"2008","journal-title":"J. Med. Case Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3747\/co.20.1230","article-title":"Management of renal collecting duct carcinoma: A systematic review and the McMaster experience","volume":"20","author":"Dason","year":"2013","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540.e13","DOI":"10.1016\/j.urolonc.2017.04.010","article-title":"Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database","volume":"Volume 35","author":"Sui","year":"2017","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"ref_6","unstructured":"National Comprehensive Cancer Network (2020, August 01). NCCN Clinical Practical Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.04.007","article-title":"Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study","volume":"100","author":"Sheng","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_8","first-page":"133","article-title":"[Metastatic collecting duct carcinoma with relatively long-term survival treated with sunitinib: A case report]","volume":"60","author":"Takeshima","year":"2014","journal-title":"Hinyokikakiyo. Acta Urol. Jpn."},{"key":"ref_9","first-page":"714","article-title":"Collecting duct carcinoma of the kidney. A contribution of 4 new cases","volume":"67","author":"Delgdo","year":"2014","journal-title":"Arch. Esp. Urol."},{"key":"ref_10","first-page":"988","article-title":"Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report","volume":"7","author":"Mizutani","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13173","DOI":"10.1097\/MD.0000000000013173","article-title":"Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy","volume":"97","author":"Yasuoka","year":"2018","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s13691-019-00389-z","article-title":"Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney","volume":"9","author":"Watanabe","year":"2020","journal-title":"Int. Cancer Conf. J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vogelzang, N.J., Olsen, M.R., McFarlane, J.J., Arrowsmith, E., Bauer, T.M., Jain, R.K., Somer, B., Lam, E.T., Kochenderfer, M.D., and Molina, A. (2020). Safety and Efficacy of Nivolumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb\/IV CheckMate 374 Study. Clin. Genitourin. Cancer.","DOI":"10.1016\/j.clgc.2020.05.006"},{"key":"ref_14","first-page":"54","article-title":"Collecting duct carcinoma of kidney","volume":"15","author":"Srigley","year":"1998","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PAP.0000000000000138","article-title":"Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas","volume":"24","author":"Yoon","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/pin.12667","article-title":"High grade infiltrative adenocarcinomas of renal cell origin: New insights into classification, morphology, and molecular pathogenesis","volume":"68","author":"Singh","year":"2018","journal-title":"Pathol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/annonc\/mdt423","article-title":"Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma","volume":"24","author":"Bigot","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_18","unstructured":"National Comprehensive Cancer Network (2020, August 01). NCCN Clinical Practical Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_19","unstructured":"National Comprehensive Cancer Network (2020, August 01). NCCN Clinical Practical Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4132\/jptm.2016.07.12","article-title":"Comparison of the FDA and ASCO\/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma","volume":"50","author":"Kim","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: A need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_22","first-page":"776","article-title":"HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report","volume":"35","author":"Bronchud","year":"2012","journal-title":"Oncol. Res. Treat."},{"key":"ref_23","first-page":"579","article-title":"Synchronous collecting duct carcinoma and papillary renal cell carcinoma: A case report and review of the literature","volume":"25","author":"Matei","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00005392-199707000-00079","article-title":"Retrospective Evaluation of c-erbB-2 Oncogene Amplification using Competitive PCR in Collecting Duct Carcinoma of the Kidney","volume":"158","author":"Selli","year":"1997","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.6004\/jnccn.2018.7264","article-title":"Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer","volume":"17","author":"Karass","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e21457","DOI":"10.1097\/MD.0000000000021457","article-title":"A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)","volume":"99","author":"Takahashi","year":"2020","journal-title":"Medicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2017.74.7824","article-title":"Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor\u2013Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE","volume":"36","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fonc.2020.01312","article-title":"Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric\/GEJ Cancer","volume":"10","author":"Adashek","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.6004\/jnccn.2019.7523","article-title":"Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?","volume":"18","author":"Li","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:32:28Z","timestamp":1760178748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113345"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113345","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]}}}